Fig. 3From: Cetuximab and anemia prevention in head and neck cancer patients undergoing radiotherapyOverall survival for head and neck squamous cell carcinoma with baseline anemia (n = 96) with or without post-radiotherapy improvement of anemia/hemoglobin (resolution of pre-RT anemia and/or Hb increase 1 g/dl above baseline)Back to article page